BARBARA KALLENBACH-WATSON: Open Payments
NPI 1548281801 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,571 in 61 payments from 16 companies in 2025. Trend: 2023 $1,244 · 2024 $1,314 · 2025 $1,571
Food & beverage: $1,571
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $395 |
| ABBVIE INC. | 11 | $299 |
| AstraZeneca Pharmaceuticals LP | 3 | $148 |
| PFIZER INC. | 7 | $136 |
| Lilly USA, LLC | 7 | $119 |
| SANOFI-AVENTIS U.S. LLC | 3 | $66 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $60 |
| GlaxoSmithKline, LLC. | 3 | $59 |
| Exact Sciences Corporation | 3 | $55 |
| SHIELD THERAPEUTICS INC | 2 | $48 |
Products named: Ozempic, AIRSUPRA, MOUNJARO, QULIPTA, JARDIANCE, TZIELD, LINZESS, ELIQUIS.
Industry payments across TX — which companies pay providers there.
